. 2011 May 1;21(6):628–636. doi: 10.1007/s10165-011-0460-5

Table 1.

Baseline characteristics of RA patients

	Total (n = 24)	Primary nonresponders (n = 9)	Responders (n = 15)	p*
Male/female	5/19	4/5	1/14	0.047
Age, years, median (25th, 75th percentiles)	61.5 (58, 70)	69 (63, 70)	59 (57.5, 62.5)	0.07
RA duration, months, median (25th, 75th percentiles)	19.5 (5, 54.3)	14 (5, 108)	24 (6, 44)	0.90
DAS28-ESR, median (25th, 75th percentiles)	5.7 (5.1, 6.4)	6.1 (5.7, 6.8)	5.3 (4.8, 5.8)	0.040
HAQ, median (25th, 75th percentiles)	0.81 (0.59, 1.78)	1.87 (1.65, 2.25)	0.63 (0.44, 0.75)	0.0005
CRP, mg/dl, median (25th, 75th percentiles)	1.9 (0.7, 3.3)	2.1 (2.0, 6.0)	1.0 (0.5, 2.7)	0.08
ESR, mm/h, median (25th, 75th percentiles)	41.5 (26, 73)	52 (42, 93)	38 (25, 56.5)	0.042
Positive anti-CCP Abs, numbers of patients (%)	23 (95.6)	8 (88.9)	15 (100)	0.38
Positive IgM RF, numbers of patients (%)	22 (91.7)	7 (77.8)	15 (100)	0.13
SJC66, median (25th, 75th percentiles)	7.5 (5, 12)	10 (6, 13)	6 (4.5, 10.5)	0.49
TJC68, median (25th, 75th percentiles)	10.5 (5, 17.5)	13 (5, 17)	9 (4.5, 11.5)	0.11
Use of MTX (8 mg/week), numbers of patients	24^a	9	15^a	–
Use of folic acid (5 mg/week), numbers of patients	24^b	9^b	15	–
Use of PSL, numbers of patients (dose)	4	2 (10 mg/day)	2 (5 mg/day)	–

Data were obtained at the time of enrollment

RA rheumatoid arthritis, DAS28 disease activity score for 28 joints, HAQ health assessment questionnaire score, CRP C-reactive protein, ESR erythrocyte sedimentation rate, anti-CCP Abs anti-cyclic citrullinated peptide antibodies, RF rheumatoid factor, SJC66 swollen joint count in 66 joints, TJC68 tender joint count in 68 joints, MTX methotrexate, PSL prednisolone

^aTwo patients had received 6 mg/week of MTX before the introduction of infliximab therapy

^bOne patient had received 10 mg/week of folic acid

* p values are based on comparison between primary nonresponders and responders to infliximab therapy